Resource Logo
NLM AIDSLINE

Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.




 

J Virol. 2000 Oct;74(19):9328-32. Unique Identifier : AIDSLINE

We studied the combined anti-human immunodeficiency virus type 1 (HIV-1) effects of a derivative of stroma-derived factor 1beta (SDF-1beta), Met-SDF-1beta, and a modified form of RANTES, aminooxypentane (AOP)-RANTES. The antiviral agents were tested singly or in combination at 95 and 99% virus inhibitory concentrations. Clinical R5 and X4 HIV-1 isolates were used. AOP-RANTES inhibited R5 but not X4 viruses, whereas Met-SDF-1beta had the opposite effect. Combinations of these compounds inhibited mixed infections with R5 and X4 viruses (95 to 99%), whereas single drugs were less inhibitory (32 to 61%). Combinations of R5 and X4 inhibitors are promising and deserve further evaluation.

JOURNAL ARTICLE Amino Acid Sequence Anti-HIV Agents/*PHARMACOLOGY/THERAPEUTIC USE Cell Line Cytokines/CHEMISTRY/*PHARMACOLOGY/THERAPEUTIC USE Genome, Viral Human HIV Infections/*DRUG THERAPY/VIROLOGY *HIV-1/GENETICS Molecular Sequence Data Receptors, CCR5/*ANTAGONISTS & INHIB Receptors, CXCR4/*ANTAGONISTS & INHIB RANTES/ANALOGS & DERIVATIVES/*PHARMACOLOGY/THERAPEUTIC USE Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S.



 




Information in this article was accurate in December 30, 2000. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.